Nuvectis reported a net loss attributable to common shareholders of $28871000 for Q4 2025, with research and development expenses of $18153000 and general and administrative expenses of $9421000. Cash and cash equivalents increased to $31634000 as of December 31, 2025.

For Q3 2025, Nuvectis reported a net loss attributable to common shareholders of $9891000 and diluted EPS of -$0.44. Research and development expenses rose to $5774000 and general and administrative expenses were $2020000. Cash and cash equivalents increased to $35442000 as of September 30, 2025.

For Q2 2025, Nuvectis reported a net loss of $6334000 with diluted EPS of -$0.30. Research and development expenses were $3613000 and general and administrative expenses were $2982000. Cash and cash equivalents increased to $26793000 as of June 30, 2025.

Nuvectis Pharma, Inc. reported a net loss of $5.3 million for the first quarter of 2025, an increase from $4.2 million in the same period last year. The company completed a $15.5 million financing, extending its projected cash runway into Q1 2027, and reported $29.9 million in cash and cash equivalents as of March 31, 2025.

Nuvectis Pharma reported its full year 2024 financial results, highlighting progress in the development of its clinical-stage drug candidates NXP800 and NXP900, a follow-on offering providing $15.5 million in gross proceeds, and an extension of the company's cash runway into 2027.

Nuvectis Pharma reported a net loss of $4.2 million for the third quarter of 2024. The company's cash, cash equivalents, and short-term investments were $17.2 million as of September 30, 2024. The company is continuing to advance the development programs of NXP800 and NXP900.

Nuvectis Pharma reported a net loss of $4.4 million for the second quarter of 2024, with cash and cash equivalents totaling $18.1 million as of June 30, 2024. The company is advancing clinical trials for NXP800 and NXP900 and managing financial resources effectively.

Nuvectis Pharma reported a net loss of $4.2 million for Q1 2024, compared to $4.0 million for Q1 2023. The company's cash and cash equivalents increased slightly to $19.5 million. Clinical development programs for NXP800 and NXP900 continued to advance.

Nuvectis Pharma reported its fiscal year 2023 financial results, highlighting progress with its clinical-stage drug candidates NXP800 and NXP900, including the initiation of clinical trials and presentation of preclinical data. The company's cash and cash equivalents were $19.1 million as of December 31, 2023, and the net loss for the year was $22.3 million.

Nuvectis Pharma reported its third quarter 2023 financial results, with a net loss of $5.9 million and cash, cash equivalents, and short-term investments of $22.1 million. The company is advancing the development programs of NXP800 and NXP900, with preliminary data from the NXP800 Phase 1b study expected in 1Q 2024.

Nuvectis Pharma reported its Q2 2023 financial results, highlighting progress in its NXP800 and NXP900 development programs. The company initiated a Phase 1b clinical trial for NXP800 and expects to initiate a Phase 1a dose escalation study for NXP900 this quarter. Nuvectis significantly strengthened its financial position, ending the quarter with approximately $24.6 million in cash, expected to support planned operations into H1 2025.

Nuvectis Pharma announced that the FDA cleared the Investigational New Drug Application for NXP900, including the Phase 1 clinical trial protocol. Nuvectis now has two precision oncology, clinical-stage drug candidates, NXP800 and NXP900.

Nuvectis Pharma reported its financial results for the fiscal year 2022. The company's cash, cash equivalents, and short-term investments were $20.0 million as of December 31, 2022, and the net loss was $19.1 million for the year ended December 31, 2022.